Predict your next investment

HEALTHCARE | Biotechnology
abbisko.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$263M

Date of IPO

10/13/2021

Market Cap

7.39B

About Abbisko Therapeutics

Abbisko Therapeutics (02256.HK) focuses on small molecule immunomodulators for cancers prevalent in Asia, using a combination of in-house R&D and outside CROs.

Abbisko Therapeutics Headquarter Location

Zhangjiang Hi-Tech Park 898 Harley Rd. Building 3

Shanghai, Shanghai, 100004,

China

+86 021-38122901

Latest Abbisko Therapeutics News

Abbisko raises $226M in Hong Kong IPO to develop new solid tumor treatment

Oct 20, 2021

See original article here -> post Abbisko Cayman Ltd. has raised $226 million through an IPO in Hong Kong, where it launched with an initial price of HK$12.46 (US$1.60) per share…. Related

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abbisko Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abbisko Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Abbisko Therapeutics Patents

Abbisko Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/13/2018

11/23/2021

Clusters of differentiation, Experimental cancer drugs, Transcription factors, Oncology, Immunology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/13/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Experimental cancer drugs, Transcription factors, Oncology, Immunology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Abbisko Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abbisko Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.